To explore whether TRIM22 promotes GBM cell proliferation through the SPHK2/MAPK signaling pathway, K145, an SPHK2 inhibitor, and selumetinib, a highly potent non-ATP-competitive MEK1/2 inhibitor, were used for in vivo and in vitro experiments. This evidence concerns the gene MAP2K1 and glioblastoma.